Home PACS News PACS Corporate News Malvern biopharm firm licenses drug-delivery technology to Duke - Philadelphia Business Journal
Malvern biopharm firm licenses drug-delivery technology to Duke - Philadelphia Business Journal PDF Print E-mail
Written by PACSMule Administrator   
Friday, 25 March 2016 05:10
Malvern biopharm firm licenses drug-delivery technology to Duke - Philadelphia Business Journal

PhaseBio's CEO Jonathan Mow

PhaseBio Pharmaceuticals[1] Inc. has entered into a deal giving the exclusive rights to its drug-delivery technology for use in treating cancer to Duke University[2].

PhaseBio of Malvern, Pa., has retained development and commercialization rights to all other applications of its elastin-like polypetide [ELP] technology platform.

PhaseBio's CEO Jonathan Mow

Elastin is a protein found in the skin and tissue of the body that helps to keep skin flexible but tight, providing a bounce-back reaction if skin is pulled.

PhaseBio is focused on the development of genetically engineered polymers[3] to improve drug delivery. Its genetically engineered polymers, which are long chains of molecules, are designed to control the rate of a drug’s absorption into a patient’s circulatory system. Slowing the absorption rate increases the half-life of a drug, which means less drug can be used and the risk of adverse side effects reduced.

References

  1. ^ PhaseBio Pharmaceuticals (www.bizjournals.com)
  2. ^ Duke University (www.bizjournals.com)
  3. ^ focused on the development of genetically engineered polymers (www.bizjournals.com)

Read more